A detailed history of D.A. Davidson & Co. transactions in Abb Vie Inc. stock. As of the latest transaction made, D.A. Davidson & Co. holds 246,645 shares of ABBV stock, worth $44.4 Million. This represents 0.41% of its overall portfolio holdings.

Number of Shares
246,645
Previous 251,378 1.88%
Holding current value
$44.4 Million
Previous $43.1 Million 12.97%
% of portfolio
0.41%
Previous 0.39%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$163.84 - $199.33 $775,454 - $943,428
-4,733 Reduced 1.88%
246,645 $48.7 Million
Q2 2024

Jul 31, 2024

BUY
$154.79 - $180.76 $298,744 - $348,866
1,930 Added 0.77%
251,378 $43.1 Million
Q1 2024

May 13, 2024

SELL
$159.82 - $182.1 $45,548 - $51,898
-285 Reduced 0.11%
249,448 $45.4 Million
Q4 2023

Feb 09, 2024

SELL
$137.6 - $154.97 $596,083 - $671,330
-4,332 Reduced 1.71%
249,733 $38.7 Million
Q3 2023

Nov 08, 2023

BUY
$133.59 - $154.65 $459,015 - $531,377
3,436 Added 1.37%
254,065 $37.9 Million
Q2 2023

Aug 10, 2023

SELL
$132.51 - $164.9 $1.11 Million - $1.38 Million
-8,341 Reduced 3.22%
250,629 $33.8 Million
Q1 2023

Apr 25, 2023

SELL
$144.61 - $166.54 $4.83 Million - $5.56 Million
-33,381 Reduced 11.42%
258,970 $41.3 Million
Q4 2022

Feb 03, 2023

BUY
$138.31 - $165.87 $335,263 - $402,068
2,424 Added 0.84%
292,351 $47.3 Million
Q3 2022

Nov 07, 2022

SELL
$134.21 - $153.93 $1.14 Million - $1.31 Million
-8,523 Reduced 2.86%
289,927 $39.1 Million
Q2 2022

Jul 28, 2022

SELL
$137.62 - $174.96 $1.26 Million - $1.6 Million
-9,121 Reduced 2.97%
298,450 $45.7 Million
Q1 2022

May 12, 2022

SELL
$131.98 - $163.75 $1.5 Million - $1.86 Million
-11,338 Reduced 3.56%
307,571 $49.9 Million
Q4 2021

Jan 31, 2022

SELL
$107.43 - $135.93 $191,762 - $242,635
-1,785 Reduced 0.56%
318,909 $43.2 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $1.63 Million - $1.85 Million
15,357 Added 5.03%
320,694 $34.6 Million
Q2 2021

Aug 10, 2021

BUY
$105.21 - $117.21 $1.39 Million - $1.55 Million
13,200 Added 4.52%
305,337 $34.4 Million
Q1 2021

May 07, 2021

BUY
$102.3 - $112.62 $9.12 Million - $10 Million
89,126 Added 43.9%
292,137 $31.6 Million
Q4 2020

Feb 10, 2021

BUY
$80.49 - $108.67 $462,415 - $624,309
5,745 Added 2.91%
203,011 $21.7 Million
Q3 2020

Nov 02, 2020

SELL
$85.91 - $100.83 $107,559 - $126,239
-1,252 Reduced 0.63%
197,266 $17.3 Million
Q2 2020

Aug 10, 2020

SELL
$73.37 - $98.18 $4.27 Million - $5.71 Million
-58,188 Reduced 22.67%
198,518 $19.5 Million
Q1 2020

May 05, 2020

BUY
$64.5 - $97.79 $1.22 Million - $1.85 Million
18,879 Added 7.94%
256,706 $19.5 Million
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $2.07 Million - $2.59 Million
28,648 Added 13.7%
237,827 $21.1 Million
Q3 2019

Nov 05, 2019

BUY
$62.98 - $75.72 $3.49 Million - $4.19 Million
55,338 Added 35.97%
209,179 $15.8 Million
Q2 2019

Aug 13, 2019

SELL
$65.7 - $83.98 $199,990 - $255,635
-3,044 Reduced 1.94%
153,841 $11.2 Million
Q1 2019

May 13, 2019

SELL
$77.14 - $90.79 $338,721 - $398,658
-4,391 Reduced 2.72%
156,885 $12.9 Million
Q4 2018

Jan 29, 2019

BUY
$77.85 - $96.01 $18,839 - $23,234
242 Added 0.15%
161,276 $14.9 Million
Q3 2018

Nov 13, 2018

SELL
$88.91 - $98.84 $28,717 - $31,925
-323 Reduced 0.2%
161,034 $15.2 Million
Q2 2018

Aug 02, 2018

BUY
$89.78 - $106.23 $586,173 - $693,575
6,529 Added 4.22%
161,357 $15 Million
Q1 2018

May 04, 2018

BUY
$92.01 - $123.21 $135,254 - $181,118
1,470 Added 0.96%
154,828 $14.7 Million
Q4 2017

Feb 08, 2018

BUY
$89.56 - $98.21 $875,628 - $960,199
9,777 Added 6.81%
153,358 $14.8 Million
Q3 2017

Nov 08, 2017

BUY
$69.85 - $89.22 $203,612 - $260,076
2,915 Added 2.07%
143,581 $12.8 Million
Q2 2017

Aug 11, 2017

BUY
N/A
140,666
140,666 $0

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track D.A. Davidson & Co. Portfolio

Follow D.A. Davidson & Co. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.